Merit Medical Systems stock hits 52-week low at $67.33

MMSI hit a 52-week low of $67.33, sliding 32.84% over the past year, with market cap ~$4.03B and a P/E of 32.25. The company beat Q4 2025 revenue and EPS and provided 2026 revenue/EPS guidance above expectations (including an anticipated $7M in Wrapsody sales), while eight analysts recently lowered estimates. Despite InvestingPro flagging the stock as undervalued, Wells Fargo downgraded MMSI to Equal Weight citing fiscal-2026 guidance uncertainty and potential Q1 headwinds; Needham and Piper trimmed price targets to $101 and $106, and BTIG initiated coverage with a $107 Buy target.

Analysis

The legal/governance shock at a large server-board vendor will create immediate demand-side and counterparty ripples that are underpriced by equity markets. Customers with critical deployments will accelerate diversification of BOMs and extend qualification cycles, pressuring near-term OEM revenue cadence while benefiting larger incumbents and contract manufacturers that can credibly reallocate supply quickly. Expect distributors and smaller board suppliers to see inventory adjustments and working-capital stress over the next 1–3 quarters as firms de-risk single-vendor exposure.

In healthcare, the stock-level weakness appears driven more by guidance credibility and sentiment than by durable demand deterioration. A governance transition opens optionality — operational conservatism in guidance can be followed by capital-allocation actions (accelerated buybacks, tuck-ins) if management prioritizes EPS recovery; conversely, a cautious start to the new fiscal year could force multiple compression that’s reversible once execution visibility returns. Markets are pricing asymmetric downside near term but leave room for meaningful upside if two consecutive quarters of revenue/EPS exceed conservative guideposts.

Key catalysts and timelines: watch shipping/inventory metrics and large-customer RFPs for the server vendor over the next 30–90 days, and monitor the healthcare company’s first-quarter cadence and any announced shareholder-friendly actions over 3–12 months. Tail risks include regulatory fines, prolonged supply-chain litigation, or a governance-driven strategic pivot that dilutes near-term margins. The plausible reversal path is clear — restoration of contract flow for hardware vendors and management-backed capital returns or M&A execution for the healthcare name would each justify a swift re-rating.

Key Decisions for Investors

• Short SMCI equity (or buy SMCI Jul-2026 1:1 put spread) sized at 1–2% of book. Risk/reward: expect 25–40% downside over 1–3 months if order deferrals accelerate; limit loss to ~12% via spread or stop. Add if a major distributor issues inventory alerts or platform customers announce supplier diversification.
• Long MMSI equity sized 1–2% with a 6–12 month horizon, stop-loss at -15% from entry. Risk/reward: target 25–35% upside if management converts cautious guidance into sequential beats and initiates buybacks or tuck-in M&A. Scale in on any pullback into the first-quarter reporting window.
• Pair trade: long MMSI + short SMCI (ratio 1:1 by notional) to isolate idiosyncratic execution risk vs sector rotation. Timeframe 3–9 months; expected asymmetric payoff if healthcare execution normalizes while hardware vendor reputational issues persist.
• Tactical options hedge: buy WFC or broad-bank call protection only if systemic credit stress indicators rise (e.g., rising LIBOR/OIS spread) — allocate <0.5% notional as tail insurance to protect against contagion-triggered liquidity squeezes.